Cargando…

Selective use of sorafenib in the treatment of thyroid cancer

Sorafenib is a multiple kinase inhibitor (MKI) approved for the treatment of primary advanced renal cell carcinoma and advanced primary liver cancer. It was recently approved by several health agencies around the world as the first available MKI treatment for radioactive iodine-refractory advanced a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitoia, Fabián, Jerkovich, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795584/
https://www.ncbi.nlm.nih.gov/pubmed/27042004
http://dx.doi.org/10.2147/DDDT.S82972